“age-related-macular-degeneration” Archives

in
Entry Author Date Location
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More 09/14/18 National
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
Unity Biotech Files IPO to Bring Anti-Aging Drugs into Clinical Trials 04/06/18 San Francisco
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
As AMD Race Tightens, Regeneron’s Second Eye Drug Combo Falls Short 11/27/17 New York
Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More 08/18/17 National
Ophthotech’s Final Try at Combo Eye Drug Comes up Short 08/14/17 New York
After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials 03/27/17 Detroit Ann Arbor
After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies 12/16/16 New York
Ocular Therapeutix Inks Licensing Deal With Regeneron For Wet AMD 10/13/16 Boston
Inspyr Leaves San Antonio for California to Be Near Clinical Trials 10/12/16 Texas
Inspyr Seeks Clinical Partner for Cash After New Name, Exec Hires 08/09/16 Texas
With One Trial Shelved And Another Failed, StemCells To Shut Down 05/31/16 San Francisco
Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy 07/02/15 Boston
Ocular’s Long-Lasting Eye Drug Tech Passes First Late-Stage Test 03/10/15 Boston
Ophthotech Prices IPO at $22 Per Share, Reels in $167M 09/24/13 New York
East Coast Life Sciences Roundup: Epizyme, Rodin, Ophthotech, & More 08/16/13 Boston
Ophthotech Eyes $85M IPO With Late-Stage Clinical Trial in Sight 08/15/13 New York
East Coast Life Sciences Roundup: KiiLN, Celgene, Acceleron, & More 08/09/13 New York
Regeneron Targets New Market for Blockbuster Eye Drug 08/06/13 New York
Ophthotech Nabs $175M To Fund Late-Stage Trial For Eye Drug 05/29/13 New York
Acucela, Turning 10, Gears Up for Pivotal Test With Eye Drug 06/12/12 Seattle
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire Vet as CEO 05/15/12 Boston
Regeneron Debuts Eye Drug, as Rivals Race to Grab Share of Hot Market 12/01/11 New York
Imagen Biotech, Staffed With Eyetech Vets, Launches in NYC With Plan to Tackle Eye Diseases 10/25/11 New York
Advanced Cell Technology Starts Human Trials of Embryonic Stem Cells Under Strict FDA Supervision 07/20/11 Boston
Regeneron’s AMD Drug Gets Priority Review With FDA 04/18/11 New York
Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News 09/02/10 San Diego
Page 1 of 2 next page »